In our longitudinal pilot study, High Mobility Group Box 1 protein (HMGB1) was found to be a promising biomarker to monitor tumor response in definitive radiochemotherapy for head and neck squamous cell carcinoma. This evidence concerns the gene HMGB1 and head and neck squamous cell carcinoma.